Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Other(1)

Detailed Status

Active, not recruiting1
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

active_not_recruiting133%
unknown133%
completed133%

Recent Activity

1 active trials
Showing 3 of 3
completednot_applicable

Genotype Expression and Phenotype of Endothelial Cells, Carrying an ACVRL1, ENG or SMAD4 Mutation, in Response to BMP9 for the Identification of New Therapeutic Targets in Hereditary Haemorrhagic Telangiectasia

NCT05632484
active_not_recruitingnot_applicable

Advancing Early Bone Health: New Frontiers for Osteoporosis Prevention

NCT06750523
unknown

Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays

NCT04023929

Clinical Trials (3)

Showing 3 of 3 trials
NCT05632484Not Applicable

Genotype Expression and Phenotype of Endothelial Cells, Carrying an ACVRL1, ENG or SMAD4 Mutation, in Response to BMP9 for the Identification of New Therapeutic Targets in Hereditary Haemorrhagic Telangiectasia

Completed
NCT06750523Not Applicable

Advancing Early Bone Health: New Frontiers for Osteoporosis Prevention

Active Not Recruiting
NCT04023929

Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
3